Wednesday, June 10, 2026
πŸ‡ΊπŸ‡Έ FDA

pharma Β· Asthma Β· Type 2 Diabetes

AstraZeneca

AstraZeneca clinical programs β€” 92 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
NMPA registrant Type
Company details
Status
Public
HQ
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
Employees
79,242
Programs
129
Drugs
77
Patents
25
Official website β†— All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis β†’
Intelligence Β· Clinical Programs

AstraZeneca projects

92 ClinicalTrials.gov programs sponsored by AstraZeneca.

AstraZeneca has 92 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

92 programs

Clinical programs

Page 1 of 2

  1. AZD0780

    AstraZeneca

    Heterozygous Familial Hypercholesterolaemia

    phase 3 small molecule active

    1 trial

  2. AZD0780

    AstraZeneca

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  3. AZD0901

    AstraZeneca

    Gastric Cancer

    phase 3 small molecule active

    2 trials

  4. AZD9291 80 mg/40 mg

    AstraZeneca

    Stage IB-IIIA Non-small Cell Lung Carcinoma

    phase 3 small molecule active

    1 trial

  5. Acalabrutinib

    AstraZeneca

    Untreated Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  6. Aclidinium bromide/formoterol Fixed-Dose Combination

    AstraZeneca

    COPD

    phase 3 small molecule completed

    1 trial

  7. Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)

    AstraZeneca

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    1 trial

  8. Anifrolumab

    AstraZeneca

    Systemic Lupus Erythematosus

    phase 3 mab active

    1 trial

  9. Anifrolumab

    AstraZeneca

    Cutaneous Lupus Erythematosus

    phase 3 other active

    1 trial

  10. Anifrolumab

    AstraZeneca

    Active Systemic Lupus Erythematosus

    phase 3 mab completed

    3 trials

  11. Anifrolumab

    AstraZeneca

    Lupus Nephritis

    phase 3 small molecule active

    1 trial

  12. BGF MDI 320/14.4/9.6 ΞΌg

    AstraZeneca

    COPD (Chronic Obstructive Pulmonary Disease)

    phase 3 small molecule active

    1 trial

  13. BGF MDI 320/28.8/9.6 ΞΌg

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial

  14. BGF MDI HFO 320/14.4/9.6ΞΌg

    AstraZeneca

    COPD (Chronic Obstructive Pulmonary Disease)

    phase 3 small molecule completed

    1 trial

  15. Baxdrostat

    AstraZeneca

    Primary Hyperaldosteronism

    phase 3 small molecule active

    1 trial

  16. Baxdrostat

    AstraZeneca

    Uncontrolled Hypertension

    phase 3 small molecule completed

    2 trials

  17. Benralizumab

    AstraZeneca

    Asthma

    phase 3 mab completed

    1 trial

  18. Benralizumab

    AstraZeneca

    Chronic Obstructive Pulmonary Disease

    phase 3 mab completed

    1 trial

  19. Benralizumab 30 mg

    AstraZeneca

    Nasal Polyposis

    phase 3 mab terminated

    1 trial

  20. Budesonide

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial

  21. Budesonide/formoterol Turbuhaler

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial

  22. Capivasertib

    AstraZeneca

    Triple Negative Breast Neoplasms

    phase 3 small molecule active

    1 trial

  23. Cediranib

    AstraZeneca

    Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  24. Cediranib

    AstraZeneca

    Recurrent Glioblastoma

    phase 3 small molecule completed

    1 trial

  25. D1447C00001

    AstraZeneca

    Bipolar Disorder

    phase 3 small molecule completed

    1 trial

  26. D3612L00005

    AstraZeneca

    HR+ / HER2- advanced breast cancer

    phase 3 small molecule active

    1 trial

  27. D6402C00012

    AstraZeneca

    Heart Failure and Impaired Kidney Function

    phase 3 small molecule active

    1 trial

  28. Dapagliflozin

    AstraZeneca

    Heart Failure With Preserved Ejection Fraction

    phase 3 small molecule completed

    1 trial

  29. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  30. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule completed

    3 trials

  31. Dapagliflozin

    AstraZeneca

    Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

    phase 3 small molecule completed

    1 trial

  32. Dapagliflozin

    AstraZeneca

    Heart Failure With Preserved Ejection Fraction (HFpEF)

    phase 3 small molecule completed

    1 trial

  33. Dapagliflozin 10 mg

    AstraZeneca

    Diabetes Mellitus, Non-Insulin-Dependent

    phase 3 small molecule completed

    1 trial

  34. Dapagliflozin 10 mg

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  35. Dato-DXd

    AstraZeneca

    Breast Cancer

    phase 3 small molecule active

    2 trials

  36. Docetaxel

    AstraZeneca

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  37. Durvalumab

    AstraZeneca

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  38. Durvalumab

    AstraZeneca

    Advanced Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  39. Durvalumab

    AstraZeneca

    Cancer

    phase 3 small molecule active

    1 trial

  40. Durvalumab

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    1 trial

  41. Durvalumab

    AstraZeneca

    Hepatocellular Carcinoma

    phase 3 small molecule active

    2 trials

  42. Durvalumab

    AstraZeneca

    Locally Advanced Cervical Cancer

    phase 3 mab completed

    1 trial

  43. Durvalumab

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    2 trials

  44. Durvalumab

    AstraZeneca

    Non Small Cell Lung Cancer NSCLC

    phase 3 small molecule active

    1 trial

  45. Durvalumab + SoC chemotherapy

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  46. Experimental: Tezepelumab

    AstraZeneca

    Asthma

    phase 3 mab completed

    1 trial

  47. Gefitinib

    AstraZeneca

    NSCLC

    phase 3 small molecule completed

    1 trial

  48. Gefitinib

    AstraZeneca

    Non-Small-Cell Lung Carcinoma

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does AstraZeneca have?

92 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.